Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Ventilator-associated pneumonia and ventilator-associated treakeabronchitis in respiratory tract infections associated with ventilator are common infections in intensive care unit and cause significant morbidity, mortality and health expenditures in nosocomial infections. Adequate and effective oral care by nurses in intensive care patients, possible complications, intensive care unit stay in the intensive care unit and is very important in terms of mortality.
The aim of this study will (1) evaluate the effect of 0.12% chlorhexidine gluconate on ventilator-associated pneumonia, ventilator-associated treakeabronchitis, (2) determine the effect of preventing microorganism colonization, and (3) assess the mortality rate for each patient and the cost-effectiveness in the health expenditures.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group | Experimental | 0.12% chlorhexidine gluconate |
|
| Placebo group | Placebo Comparator | sodium bicarbonate |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 0.12% chlorhexidine gluconate | Drug | The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pathogen colonization change | We will examine microbiological analyses ( mini-BAL, oropharyngeal and tracheal secretions) | change from baseline pathogen colonization at Day 3 |
| Oral assessment guide score change | The score ranges from 8 to 24 and higher scores indicating worse oral health | at the time of admission into the study (day 0), at study day 2 and at day 3 |
| Clinical pulmonary infection score change | The score ranges from 0 to 12 (ventilator-associated pneumonia ≥ 6 ) | at the time of admission into the study (day 0), at study day 2 and at day 3 |
| rate of tracheobronchitis change | Questionary (use the rate of tracheobronchitis categories) | change from baseline the rate of tracheobronchitis at Day 3 |
| Measure | Description | Time Frame |
|---|---|---|
| cost effectiveness | We used the decision tree modelling for estimating the cost-effectiveness of antiseptic solutions. | Day 30 |
| Mortality | rate of mortality |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Karabük University Training and Research Hospital | Karabük | Karabük Province | 78050 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D053717 | Pneumonia, Ventilator-Associated |
| ID | Term |
|---|---|
| D000077299 | Healthcare-Associated Pneumonia |
| D003428 | Cross Infection |
| D007239 | Infections |
| D011014 | Pneumonia |
Not provided
Not provided
| ID | Term |
|---|---|
| C010882 | chlorhexidine gluconate |
| D017693 | Sodium Bicarbonate |
| ID | Term |
|---|---|
| D001639 | Bicarbonates |
| D002254 | Carbonates |
| D002255 | Carbonic Acid |
| D017554 | Carbon Compounds, Inorganic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care |
|
|
| Day 7 and Day 28 |
| D012141 |
| Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007049 | Iatrogenic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007287 |
| Inorganic Chemicals |
| D017670 | Sodium Compounds |